1
|
Precursor B-Cell Acute Lymphoblastic Leukemia With MYC and BCL2 Rearrangements Presenting as Extensive Extranodal Disease in an Adolescent. J Pediatr Hematol Oncol 2021; 43:e501-e504. [PMID: 33448716 DOI: 10.1097/mph.0000000000002051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Accepted: 11/25/2020] [Indexed: 11/25/2022]
Abstract
Combined rearrangements of MYC and BCL2 are rare in precursor B-cell acute lymphoblastic leukemia (B-ALL). A 14-year-old boy presented with swelling of the knee and face. Imaging revealed diffuse infiltration of lacrimal glands, parotid glands along with the extensive epidural disease. Morphology and immunophenotype of knee joint aspirate were consistent with precursor B-ALL. Fluorescent in situ hybridization identified rearrangements of MYC and BCL2 genes. The disease was refractory to intensive treatment. The patient died of progressive disease. Precursor B-ALL with combined MYC and BCL2 rearrangements is rare, characterized by an aggressive clinical course, and has an inadequate response to standard therapeutic approaches.
Collapse
|
2
|
Burkitt Leukemia With Precursor B-Cell Immunophenotype and Dual Translocation of t(14;18) and t(8;14) in a Child: Case Report and Review of the Literature. J Pediatr Hematol Oncol 2020; 42:e61-e63. [PMID: 30499905 DOI: 10.1097/mph.0000000000001354] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Burkitt leukemia (BL) with the precursor B-cell immunophenotype is a rarely reported condition. The prognosis of such patients is similar to that of classic BL. However, the combination of chromosomal translocations associated with bcl-2 and c-myc rearrangement has a poor prognosis. OBSERVATIONS An 11-year-old child presented with fever and weakness. Bone marrow aspiration showed morphologically L1 type blasts and flow cytometry analysis was compatible with precursor B-cell immunophenotype. Cytogenetic analysis revealed a combination of t(8;14) and t(14;l8). CONCLUSIONS The combination of t(8;14) and t(14;l8) can exhibit different immunophenotypical and morphologic features in leukemias.
Collapse
|
3
|
Stratmann JA, von Rose AB, Koschade S, Wendelin K, Köhler F, Heinsch M, Schiller K, Haferlach C, Wattad M, Rieder H, Serve H, Gökbuget N, Steffen B. Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma. Ann Hematol 2019; 98:647-656. [PMID: 30613837 DOI: 10.1007/s00277-018-03590-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2018] [Accepted: 12/25/2018] [Indexed: 12/22/2022]
Abstract
The 2016 revised World Health Organization (WHO) classification of lymphoid neoplasms included the category of high-grade B cell lymphomas (HGBLs) with combined MYC and BCL2 and/or BCL6 rearrangements (double-hit, DH). However, the clinical features of B cell precursor leukemia (BCP-ALL) that harbor DH genetics remain widely unknown. We performed a retrospective analysis of the German Multicenter Study Group for Adult ALL registry and a literature search for de novo DH-BCP-ALLs. We identified 6 patients in the GMALL registry and 11 patients published in the literature between 1983 and June 2018. Patients of all ages (range, 15-86 years) are affected. There is a high incidence of meningeal disease and other extramedullary disease manifestations. Current treatment approaches are mainly ALL-based and are sufficient to induce first complete remissions, but progression-free survival is only 4.0 months (95% CI, 1.5-6.5 months) and all patients succumb to their disease, once relapsed, with a median survival of 5.0 months (95% CI, 3.1-6.9 months), despite intensive salvage and targeted therapy approaches. Of all patients, only two that attained an initial complete remission were alive at data cutoff. In all cases, the BCL2 gene was rearranged to be in proximity to the IGH locus, whereas MYC had various translocation partners juxtaposed. There was no significant survival difference between IG and non-IG translocation partners (HR, 1.03; 95% CI, 0.33-3.2; p = 0.89). In conclusion, de novo DH-BCP-ALL is an aggressive B cell malignancy with deleterious outcome. Physicians have to be aware of this rare disease subset due to the atypical clinical behavior and especially because latest classification systems do not cover this sub-entity.
Collapse
Affiliation(s)
- Jan A Stratmann
- Department of Hematology and Oncology, Johann Wolfgang Goethe University of Frankfurt, Theodor Stern Kai 7, 60596, Frankfurt am Main, Germany.
| | - Aaron Becker von Rose
- Department of Hematology and Oncology, Johann Wolfgang Goethe University of Frankfurt, Theodor Stern Kai 7, 60596, Frankfurt am Main, Germany
| | - Sebastian Koschade
- Department of Hematology and Oncology, Johann Wolfgang Goethe University of Frankfurt, Theodor Stern Kai 7, 60596, Frankfurt am Main, Germany
| | - Knut Wendelin
- Department of Hematology and Medical Oncology, Paracelsus Medical University, Prof.-Ernst-Nathan-Str. 1, 90419, Nuremberg, Germany
| | - Friedemann Köhler
- Department of. Internal Medicine II, Schwarzwald-Baar Clinic Villingen-Schwenningen, Klinikstr. 11, 78052, Villingen-Schwenningen, Germany
| | - Michael Heinsch
- Department of Internal Medicine II, St Johannes Hospital, An der Abtei 7-11, 47166, Duisburg, Germany
| | - Kilian Schiller
- Department of Radiation Oncology, Technical University of Munich (TUM), Ismaninger Strasse 22, 81675, Munich, Germany
| | - Claudia Haferlach
- Munich Leukemia Laboratory (MLL), Max-Lebsche-Platz 31, 81377, Munich, Germany
| | - Mohamed Wattad
- Department of Hematology and Oncology, Hospital Essen-Werden, Pattbergstraße 1-3, 45239, Essen, Germany
| | - Harald Rieder
- Institute for Human Genetics, Medical Faculty, Heinrich-Heine-University, Moorenstraße 5, 40225, Düsseldorf, Germany
| | - Hubert Serve
- Department of Hematology and Oncology, Johann Wolfgang Goethe University of Frankfurt, Theodor Stern Kai 7, 60596, Frankfurt am Main, Germany
| | - Nicola Gökbuget
- Department of Hematology and Oncology, Johann Wolfgang Goethe University of Frankfurt, Theodor Stern Kai 7, 60596, Frankfurt am Main, Germany
| | - Björn Steffen
- Department of Hematology and Oncology, Johann Wolfgang Goethe University of Frankfurt, Theodor Stern Kai 7, 60596, Frankfurt am Main, Germany
| |
Collapse
|
4
|
Uchida A, Isobe Y, Uemura Y, Nishio Y, Sakai H, Kato M, Otsubo K, Hoshikawa M, Takagi M, Miura I. De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a case report and literature review. BMC Clin Pathol 2017; 17:21. [PMID: 29151814 PMCID: PMC5679186 DOI: 10.1186/s12907-017-0060-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Accepted: 10/30/2017] [Indexed: 12/15/2022] Open
Abstract
Background B-cell lymphomas harboring the 8q24/MYC plus 18q21/BCL2 translocations are now referred to as high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-MBR). Although HGBL-MBR is frequently found in cases with diffuse large B-cell lymphoma or Burkitt lymphoma-like B-cell lymphoma, acute lymphoblastic leukemia (ALL)-like disease of HGBL-MBR (AL-HGBL-MBR) has been reported incidentally. Case presentation A 69-year-old Japanese woman developed remittent fever and increasing systemic bone pain. The bone marrow examination revealed that more than 90% of nuclear cells were blastoid cells, which were positive for CD10, CD19, CD20, and surface IgMκ and negative for terminal deoxynucleotidyl transferase (TdT). Cytogenetic studies confirmed that the patient had de novo AL-HGBL-MBR with the extra copies of MYC and loss of chromosome 17p. She showed resistance to chemoimmunotherapy and died seven months after the diagnosis. The literature review identified further 47 de novo AL-HGBL-MBR cases within the last 32 years. The median age was 61 years (range, 27 − 86); the male/female ratio was 2.0. Thirty-eight cases (79%) presented a clinical picture of ALL at diagnosis; 14 (36%) of 39 available cases showed central nervous system involvement. Loss of 17p and translocations at 2p12–13, 3q27, 9p13 were frequently observed as additional cytogenetic abnormalities. Although the median survival of 46 available cases was only five months (range, 0.1–18), rituximab use significantly improved the survival of AL-HGBL-MBR (log-rank test, P = 0.0294). Conclusion Our patient and most reported de novo AL-HGBL-MBR cases showed resistance to conventional chemoimmunotherapy and disastrous consequences. AL-HGBL-MBL is a rare, but should be considered a distinct clinical condition in HGBL-MBR. Other therapeutic strategies, such as using inhibitors of MYC and BCL2, are needed to overcome the chemoresistance of AL-HGBL-MBR.
Collapse
Affiliation(s)
- Akiko Uchida
- Division of Hematology & Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511 Japan
| | - Yasushi Isobe
- Division of Hematology & Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511 Japan
| | - Yu Uemura
- Division of Hematology & Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511 Japan
| | - Yuji Nishio
- Division of Hematology & Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511 Japan
| | - Hirotaka Sakai
- Division of Hematology & Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511 Japan
| | - Masayuki Kato
- Division of Hematology & Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511 Japan
| | - Kaori Otsubo
- Department of cytogenetics, SRL Diagnostics, Hachioji Laboratory, Tokyo, Japan
| | - Masahiro Hoshikawa
- Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan
| | - Masayuki Takagi
- Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan
| | - Ikuo Miura
- Division of Hematology & Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511 Japan
| |
Collapse
|
5
|
Liu W, Hu S, Konopleva M, Khoury JD, Kalhor N, Tang G, Bueso-Ramos CE, Jorgensen JL, Lin P, Medeiros LJ, Lu X. De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis. Pediatr Hematol Oncol 2016; 32:535-47. [PMID: 26558423 DOI: 10.3109/08880018.2015.1087611] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
MYC and BCL2 translocations in B-cell lymphomas are defined as "double-hit" associated with poor prognosis in adult patients. Such double-hit events are extremely rare in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), especially in pediatric patients or young adults. This study is to investigate the clinical manifestation of de novo MYCyBCL2 double-hit BCP-ALL in young patients. Two pediatric and one young adult patients were identified after a retrospective data review and all without previous history of lymphoma. There were two females and one male aged 15, 18, and 24, respectively. All patients had an unremarkable medical history before presenting with extensive bone marrow and central nervous system involvement at diagnosis. Flow cytometry immunophenotypic analysis showed an immature B-cell immunophenotype (CD10+, CD19+, TdT+, surface Ig-) and immunohistochemistry showed high expression of MYC and BCL2 in all cases. All patients showed complex karyotypes associated with 8q24 abnormalities in the form of t(8;9)(q24;p13) or t(8;14)(q24;q32) and t(14;18)(q32;q21) and fluorescence in situ hybridization confirmed MYC and BCL2 rearrangements. Two patients died of refractory disease or disease progression 7 and 13 months after initial diagnosis, respectively, and the third patient was treated with protocol AALL0232 under the Children's Oncology Group study, achieved complete remission and remained in remission for 53 months at last follow-up. Our study showed that De novo MYCyBCL2 double-hit BCP-ALL is a rare disease that also occurs in pediatric and young adult patients and associated with complex karyotypes and poor prognosis. Younger patients may benefit from intensified chemotherapy.
Collapse
Affiliation(s)
- Wei Liu
- a Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA.,b Department of Pathology , The First Affiliated Hospital of Soochow University , Suzhou , Jiangsu , China
| | - Shimin Hu
- a Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA
| | - Marina Konopleva
- c Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA
| | - Joseph D Khoury
- a Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA
| | - Neda Kalhor
- d Department of Pathology , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA
| | - Guilin Tang
- a Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA
| | - Carlos E Bueso-Ramos
- a Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA
| | - Jeffrey L Jorgensen
- a Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA
| | - Pei Lin
- a Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA
| | - L Jeffrey Medeiros
- a Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA
| | - Xinyan Lu
- a Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA
| |
Collapse
|
6
|
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010; 34:327-40. [PMID: 20118770 DOI: 10.1097/pas.0b013e3181cd3aeb] [Citation(s) in RCA: 292] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as "double-hit" lymphomas (DHL), are rare neoplasms characterized by highly aggressive clinical behavior, complex karyotypes, and a spectrum of pathologic features overlapping with Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and B-lymphoblastic lymphoma/leukemia (B-LBL). The clinical and pathologic spectrum of this rare entity, including comparison to other high-grade B-cell neoplasms, has not been well defined. We conducted a retrospective analysis of clinical and pathologic features of 20 cases of DHL seen at our institution during a 5-year period. In addition, we carried out case-control comparisons of DHL with BL and International Prognostic Index (IPI)-matched DLBCL. The 11 men and 9 women had a median age of 63.5 years (range 32 to 91). Six patients had a history of grade 1 to 2 follicular lymphoma; review of the prior biopsy specimens in 2 of 5 cases revealed blastoid morphology. Eighteen patients had Ann Arbor stage 3 or 4 disease and all had elevated serum lactate dehydrogenase (LDH) levels at presentation. Extranodal disease was present in 17/20 (85%), bone marrow involvement in 10/17 (59%) and central nervous system (CNS) disease in 5/11 (45%). Nineteen patients were treated with combination chemotherapy, of whom 18 received rituximab and 14 received CNS-directed therapy. Fourteen patients (70%) died within 8 months of diagnosis. Median overall survival in the DHL group (4.5 mo) was inferior to both BL (P=0.002) and IPI-matched DLBCL (P=0.04) control patients. Twelve DHL cases (60%) were classified as B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL, 7 cases (35%) as DLBCL, not otherwise specified, and 1 case as B-LBL. Distinguishing features from BL included expression of Bcl2 (P<0.0001), Mum1/IRF4 (P=0.006), Ki-67 <95% (P<0.0001), and absence of EBV-EBER (P=0.006). DHL commonly contained the t(8;22) rather than the t(8;14) seen in most BL controls (P=0.001), and exhibited a higher number of chromosomal aberrations (P=0.0009). DHL is a high-grade B-cell neoplasm with a poor prognosis, resistance to multiagent chemotherapy, and clinical and pathologic features distinct from other high-grade B-cell neoplasms. Familiarity with the morphologic and immunophenotypic spectrum of DHL is important in directing testing to detect concurrent IGH-BCL2 and MYC rearrangements when a karyotype is unavailable. The aggressive clinical behavior and combination of genetic abnormalities seen in these cases may warrant categorization as a separate entity in future classifications and call for novel therapeutic approaches.
Collapse
|
7
|
Kiefer T, Schüler F, Knopp A, Wimmer M, Hirt C, Schaefer HE, Dölken G. A human Burkitt’s lymphoma cell line carrying t(8;22) and t(14;18) translocations. Ann Hematol 2007; 86:821-30. [PMID: 17622530 DOI: 10.1007/s00277-007-0313-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2006] [Accepted: 05/07/2007] [Indexed: 10/23/2022]
Abstract
A combination of chromosomal translocations associated with bcl-2 re-arrangement (t(14;18)) and c-myc re-arrangement (t(8;14), t(8;22), or t(2;8)) is a rare event. We describe the first cell line exhibiting t(14;18) and t(8;22), which will enable us to study the interactions of bcl-2 and c-myc systematically. Cell culture was started with circulating lymphoma cells from the peripheral blood of an adult male Caucasian patient with Burkitt's lymphoma after the second relapse. The cells grew spontaneously without cytokines, fulfilled all criteria of a cell line and were analysed. An Epstein-Barr virus (EBV) genome-negative cell line (DoGKiT) has been established. RC-banding analysis of the chromosomes showed a complex karyotype with a modal number of 48, XY, dup(1)(q31;q44), t(8;22)(q24;q11), der(10), t(14;18)(q32;q21), add(16)(pter), dup(17)(q12q24), +der(18), +20. The combination of t(8;22)(q24;q11), a variant translocation of Burkitt's lymphoma and t(14;18)(q32;q21), typical for follicular lymphoma (FL), was confirmed by FISH and SKY-analysis. Surface marker studies of the cell line showed that the cells were positive for CALLA (CD10), CD19, cyCD22, cyCD79a and HLA-DR and negative for TdT, IgM, CD5 and CD23. To our knowledge, this is the first established cell line carrying these two translocations. In contrast to already established cell lines carrying the more common combination of t(8;14)(q24;q32) and t(14;18)(q32;q21) with both IgH alleles being involved in translocations, the cell line DoGKiT carries only one translocated IgH allele. This cell line may serve as an important tool in the study of the combination of the chromosomal translocations t(14;18) and t(8;22) and in molecular genetic studies of transformed FL.
Collapse
Affiliation(s)
- Thomas Kiefer
- Klinik und Poliklinik für Innere Medizin C, Hämatologie und Onkologie, Ernst-Moritz-Arndt Universität Greifswald, Sauerbruchstrasse, 17475, Greifswald, Germany
| | | | | | | | | | | | | |
Collapse
|
8
|
D'Achille P, Seymour JF, Campbell LJ. Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature. ACTA ACUST UNITED AC 2006; 171:52-6. [PMID: 17074591 DOI: 10.1016/j.cancergencyto.2006.07.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2006] [Revised: 06/30/2006] [Accepted: 07/07/2006] [Indexed: 10/24/2022]
Abstract
We present a series of 12 cases of de novo acute lymphoblastic leukemia (ALL) with translocation t(14;18)(q32;q21). The median age of patients at presentation was 65.5 years, and no patient presented with a past history or any clinical evidence of lymphoma. A Burkitt translocation was identified in 4 of the 12 cases by conventional cytogenetics but fluorescence in situ hybridization using a MYC probe identified a further three cases of MYC rearrangement: one with a cryptic t(8;14) involving the der(14)t(14;18), one showing MYC translocated onto a marker chromosome, and one associated with a t(8;9)(q24;p13) translocation. A review of the literature identified an extremely close association between the t(14;18) and the t(8;9), with the latter translocation found only in the presence of t(14;18). The present study confirms the previously reported dismal prognosis of t(14;18)-associated ALL.
Collapse
Affiliation(s)
- Pina D'Achille
- Victorian Cancer Cytogenetics Service, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
| | | | | |
Collapse
|
9
|
Hardianti MS, Tatsumi E, Syampurnawati M, Furuta K, Suzuki A, Saigo K, Kawano S, Takenokuchi M, Kumagai S, Matsuo Y, Koizumi T, Takeuchi M. Presence of somatic hypermutation and activation-induced cytidine deaminase in acute lymphoblastic leukemia L2 with t(14;18)(q32;q21). Eur J Haematol 2005; 74:11-9. [PMID: 15613101 DOI: 10.1111/j.1600-0609.2004.00338.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
AIM Acute lymphoblastic leukemia (ALL) with L2 (FAB) morphology has rarely been reported to show t(14;18)(q32;q21). We aimed to delineate the stage at which this type of ALL is derived in B-lineage differentiation. METHODS The somatic hypermutation (SHM) of the variable region of immunoglobulin heavy chain (IgV(H)) gene and the expression of terminal deoxynucleotidyl transferase (TdT), recombination-activating gene 1 and 2 (RAG-1 and -2), and activation-induced cytidine deaminase (AID) were investigated in three cell lines and two fresh samples, including a pair of matched fresh and cell line cells. RESULTS TdT, RAG-1, and RAG-2 were variably expressed. AID was expressed in four of five samples. SHM of the IgV(H) gene was found in all samples with high average frequency (11.84%) comparable with that in follicular lymphoma. Ongoing mutation was seen in two fresh samples. CONCLUSION As AID and SHM are generally regarded as properties exhibited by mature B cells, the presence of AID and SHM in this study seems to be incompatible with the general understanding of the early stage derivation of ALL in B-lineage differentiation. The results here give some insight into the relationship between disease type (ALL or lymphoma) and derivation stage, the overlapping of the early stage phenotype and the mature genomic characteristics, and the probable relationship between the mechanism of the occurrence of t(14;18)(q32;q21) and the machinery causing SHM.
Collapse
MESH Headings
- Base Sequence
- Cell Line, Tumor
- Chromosomes, Human, Pair 14/genetics
- Chromosomes, Human, Pair 18/genetics
- Cytidine Deaminase
- Cytosine Deaminase/genetics
- DNA Nucleotidylexotransferase/genetics
- DNA, Neoplasm/genetics
- DNA-Binding Proteins/genetics
- Gene Expression
- Genes, RAG-1
- Humans
- Immunoglobulin Heavy Chains/genetics
- Immunoglobulin Variable Region/genetics
- Nuclear Proteins
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/enzymology
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- RNA, Neoplasm/genetics
- RNA, Neoplasm/metabolism
- Somatic Hypermutation, Immunoglobulin
- Translocation, Genetic
Collapse
Affiliation(s)
- Mardiah Suci Hardianti
- International Center for Medical Research (ICMR), Graduate School of Medicine, Kobe University, Kobe, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Dunphy CH, van Deventer HW, Carder KJ, Rao KW, Dent GA. Mature B-cell acute lymphoblastic leukemia with associated translocations (14;18)(q32;q21) and (8;9)(q24;p13). A Burkitt variant? Arch Pathol Lab Med 2003; 127:610-3. [PMID: 12708908 DOI: 10.5858/2003-127-0610-mballw] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The translocation t(14;18)(q32;q21) is most commonly associated with follicular lymphoma but has also been described in acute lymphoblastic leukemia (ALL) of B-cell origin. Although these ALL cases have had a pre-pre-B, pre-B, or mature B-cell immunophenotype and L2 or L3 morphology, all have been associated with an abnormality of 8q24. In fact, 91% (10 of 11) have been associated with t(8;22) or t(8;14), marker chromosomes for Burkitt-type ALL. The other case was associated with del(8)(q24). Thus, Burkitt-type ALL may have various immunophenotypes and morphology when associated with t(14;18). We describe a case of mature B-cell ALL associated with t(14;18) and t(8;9)(q24;p13). The morphology was suggestive but not entirely characteristic of the L3 subtype. However, on the basis of the cytogenetic findings and the review of the literature, perhaps this case represents a variant of Burkitt-type ALL, which would be important to recognize for prognostic and therapeutic purposes. We describe our findings and review the literature to heighten awareness of this group of ALLs associated with t(14;18). Additional cases need to be accrued and documented to determine the significance of an associated abnormality of 8q24 in this setting.
Collapse
Affiliation(s)
- Cherie H Dunphy
- Department of Pathology & Laboratory Medicine, Division of Hematopathology, University of North Carolina, Chapel Hill 27599-7525, USA.
| | | | | | | | | |
Collapse
|
11
|
Stamatoullas A, Buchonnet G, Lepretre S, Lenain P, Lenormand B, Duval C, Callat MP, Gaulard P, Bastard C, Tilly H. De novo acute B cell leukemia/lymphoma with t(14;18). Leukemia 2000; 14:1960-6. [PMID: 11069032 DOI: 10.1038/sj.leu.2401910] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The t(14;18)(q32;q21) translocation is the most common translocation in B cell malignancies being found in 80% of follicular lymphomas and about 20% of diffuse large B cell lymphomas. Only rare cases of de novo acute B cell lymphoblastic leukemia with t(14;18) have been described. We describe five cases of this entity which appears to have very homogeneous clinical, phenotypic and genotypic features. None of these patients had prior history of follicular lymphoma. The disease was characterized by acute clinical features with nodal and/or extranodal disease, massive bone marrow infiltration and rapid increase of circulating blast cells of mature B cell phenotype. All patients disclosed complex chromosomal and molecular abnormalities involving at least the BCL-2 and c-MYC genes. Furthermore, three patients had evidence of BCL-6 involvement and one patient had a p53 mutation. Despite intensive chemotherapy, including for two patients allogeneic bone marrow transplantation in first complete remission, all patients died within a few months. Neuro-meningeal relapse occurred in three of the five patients in spite of neuro-meningeal prophylaxis. De novo leukemia/lymphoma with t(14;18) is a rare entity with a very poor prognosis. Whether early bone marrow transplant could modify the natural history of the disease remains to be determined. An intensive neuro-meningeal prophylaxis appears to be mandatory in these patients.
Collapse
MESH Headings
- Adult
- Antineoplastic Agents/therapeutic use
- Blast Crisis/drug therapy
- Blast Crisis/genetics
- Blast Crisis/pathology
- Bone Marrow/pathology
- Bone Marrow Transplantation
- Burkitt Lymphoma/drug therapy
- Burkitt Lymphoma/genetics
- Burkitt Lymphoma/pathology
- Burkitt Lymphoma/therapy
- Chromosomes, Human, Pair 14/genetics
- Chromosomes, Human, Pair 14/ultrastructure
- Chromosomes, Human, Pair 18/genetics
- Chromosomes, Human, Pair 18/ultrastructure
- DNA, Neoplasm/genetics
- DNA-Binding Proteins/genetics
- Disease Progression
- Female
- Genes, bcl-2
- Genes, myc
- Genes, p53
- Humans
- Immunophenotyping
- Leukemic Infiltration
- Lymphoma, B-Cell/drug therapy
- Lymphoma, B-Cell/genetics
- Lymphoma, B-Cell/pathology
- Lymphoma, B-Cell/therapy
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/genetics
- Lymphoma, Follicular/pathology
- Lymphoma, Follicular/therapy
- Male
- Meninges/pathology
- Middle Aged
- Neoplastic Cells, Circulating
- Prognosis
- Proto-Oncogene Proteins/genetics
- Proto-Oncogene Proteins c-bcl-6
- Recurrence
- Salvage Therapy
- Transcription Factors/genetics
- Translocation, Genetic
- Treatment Failure
Collapse
Affiliation(s)
- A Stamatoullas
- Département d'Hematologie, Centre Henri Becquerel, Rouen, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Berger R, Flexor M, Le Coniat M, Larsen CJ. Presence of three recurrent chromosomal reaarrangements, t(2;3)(p12;q37), del(8)(q24), and t(14;18), in an acute lymphoblastic leukemia. CANCER GENETICS AND CYTOGENETICS 1996; 86:76-9. [PMID: 8616793 DOI: 10.1016/0165-4608(95)00177-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
A complex chromosomal abnormality associating three recurrent rearrangements, t(2;3)((p12;q37), del (8)(q24) and t(14;18)(q32;q21), was detected in a patient with acute lymphoblastic leukemia of the Burkitt type. Southern blot studies showed rearrangements of the MYC, BCL2, and JH genes, thus confirming the cytogenetic data. However, no rearrangement of the LAZ3/BCL6 gene, normally localized on band 3q27, could be detected. The simultaneous presence of three recurrent rearrangements specific for lymphoid malignancies addresses the question of their timing in the malignant process and the prognostic significance of the association of such anomalies.
Collapse
MESH Headings
- Adult
- Blotting, Southern
- Chromosomes, Human, Pair 14
- Chromosomes, Human, Pair 18
- Chromosomes, Human, Pair 2
- Chromosomes, Human, Pair 3
- Chromosomes, Human, Pair 8
- Fatal Outcome
- Female
- Gene Deletion
- Humans
- Karyotyping
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
- Translocation, Genetic
Collapse
Affiliation(s)
- R Berger
- INSERM U 301, Institut de Génétique Moléculaire, Paris, France
| | | | | | | |
Collapse
|
13
|
Jaeger U, Karth GD, Knapp S, Friedl J, Laczika K, Kusec R. Molecular mechanism of the t(14;18)--a model for lymphoid-specific chromosomal translocations. Leuk Lymphoma 1994; 14:197-202. [PMID: 7950908 DOI: 10.3109/10428199409049669] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The chromosomal translocation t(14;18) occurs during early B-cell development and juxtaposes the immunoglobulin heavy chain locus (IgH) with the bcl-2 oncogene. Several factors contribute to the translocation mechanism: (1) The rearrangement of the chromosome 14 DH and JH translocation partners has typical features of V(D)J-recombinase-mediated joining with N-segment addition. (2) The bcl-2 major (mbr) and minor (mcr) breakpoint regions as well as their IgH reciprocal counterparts contain recombinatorial sequences related to chi or the minisatellite-core which bind at least one common DNA-binding protein (bp45). Similar elements are found at the breakpoints of other lymphoid-specific translocations like the t(11;14), t(2;8) or the t(4;11). (3) Structural analysis of the bcl-2 mbr indicates that this region may adopt alternative DNA-configurations which can promote recombination and is cleaved by an endogenous nuclease present in early B-cells. The present data suggest that V(D)J-recombinase as well as chi/minisatellite-core mediated recombination contribute to the mechanism and make the t(14;18) a model system for lymphoid-specific reciprocal translocations.
Collapse
Affiliation(s)
- U Jaeger
- Department of Internal Medicine, University of Vienna, Austria
| | | | | | | | | | | |
Collapse
|